Innovent Biologics Bullish on China Obesity Drug Outlook

Innovent Biologics has reported its first profit even as competition from weight-loss generics looms. Speaking exclusively to Bloomberg's The China Show, CFO Rachel You says China's obesity drug market has massive potential and could mirror current penetration rates in the US. (Source: Bloomberg)